Close
FINDING CURES TOGETHER<sup>SM</sup>

Sixth AACR-IASLC International Joint Conference: Lung Cancer Translational Science from the Bench to the Clinic

​Program 

Saturday, January 11, 2020

Sunday, January 12, 2020


Monday, January 13, 2020


Tuesday, January 14, 2020



Saturday, January 11

Plenary Session 1: Therapeutic Targeting and Vulnerabilities of Ras-Driven Lung Cancer
Session Chair: John V. Heymach, The University of Texas MD Anderson Cancer Center, Houston, Texas
4:30-6:15 p.m.

Title to be announced
Ferdinandos Skoulidis, The University of Texas MD Anderson Cancer Center, Houston, Texas

Insights into KRAS biology to identify potential therapeutic strategies
Chiara Ambrogio, Dana-Farber Cancer Institute, Boston, Massachusetts

Therapeutic approaches in KRAS driven non-small cell lung cancer
Caroline McCoach, University of California San Francisco School of Medicine, San Francisco, California

Transcriptional subtypes resolve tumor heterogeneity and identify therapeutic vulnerabilities in lung cancer*
Jonathan Cooper, Genentech, Inc., South San Francisco, California

The SHP2 inhibitor RMC-4630 in patients with KRAS-mutant non-small cell lung cancer: Preliminary evaluation of a first-in-man phase 1 clinical trial*
Sai-Hong Ignatius Ou, University of California Irvine, Irvine, California


Break
6:15-6:30 p.m.


Welcome Remarks and Opening Keynote
6:30-7:30 p.m.

Early-stage drug development in the 21st century^
William Pao, Roche Innovation Center Basel, Basel, Switzerland


Opening Reception
7:30-9:30 p.m.


Top of page


Sunday, January 12

Continental Breakfast
7-8 a.m.


Plenary Session 2: Lung Preneoplasia and Early Detection
Session Chair: Pierre Massion, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
8-9:30 a.m.

Genomic underpinnings of tumor behavior in in situ and early lung adenocarcinoma
Pierre Massion

Intercepting lung cancer by understanding premalignant changes in the airway field
Jennifer E. Beane, Boston University School of Medicine, Boston, Massachusetts

Plasma proteomic, glycomic, and autoantibody biomarkers for lung cancer early detection
Paul D. Lampe, Fred Hutchinson Cancer Research Center, Seattle, Washington

The genome-wide mutational landscape of lung cancer in never-smokers: The Women’s Health Initiative (WHI) cohort*
Sitapriya Moorthi, Fred Hutchinson Cancer Research Center, Seattle, Washington


Break
9:30-10 a.m.


Plenary Session 3: Metabolism
Session Chair: David B. Shackelford, UCLA David Geffen School of Medicine, Los Angeles, California
10-11:30 a.m.

Mapping mitochondrial heterogeneity in lung cancer
David B. Shackelford

Identification of new therapeutic targets in non-small cell lung cancer
Kathryn A. O'Donnell, UT Southwestern Medical Center, Dallas, Texas

Novel metabolic functions for redox regulators in non-small cell lung cancer
Gina M. DeNicola, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida

Integrated proteometabolomic analysis reveals metabolic vulnerabilities in small-cell lung cancer*
Antony Prabhu, H. Lee Moffitt Cancer Center, Tampa, Florida


Poster Session A Highlights
Session Chair: Christine M. Lovly, Vanderbilt University School of Medicine, Nashville, Tennessee
11:35 a.m.

(A03) Lung adenocarcinoma resident microbiome may contribute to cancer hypomethylation status
Erin Marshall, BC Cancer Research Centre, Vancouver, BC, Canada

(A05) ART1, a mono-ADP-ribosyltransferase, regulates tumor-infiltrating CD8+ T cells and is highly expressed in EGFR-mutated lung cancers
Sumit Mukherjee, Weill Cornell Medicine, New York, New York

(A06) Tri-complex inhibitors of the oncogenic, GTP-bound form of KRASG12C overcome RTK-mediated escape mechanisms and drive tumor regressions in preclinical models of NSCLC
Robert Nichols, Revolution Medicines, Redwood City, California

(A07) The genomic landscape of SMARCA4 alterations and association with patient outcomes in lung cancer
Adam Schoenfeld, Memorial Sloan Kettering Cancer Center, New York, New York

(A08) MYC-driven SCLC has unique metabolic vulnerabilities
Sarah Wait, Huntsman Cancer Institute, Salt Lake City, Utah


Poster Session A / Lunch
12-2 p.m.


Plenary Session 4: Precision Immunotherapy
Session Chair: Katerina A. Politi, Yale Cancer Center, New Haven, Connecticut
2-4 p.m.

Role of the tumor microenvironment in sensitivity and resistance to immunostimulatory therapies in NSCLC
Kurt A. Schalper, Yale University, New Haven, Connecticut

Liquid biopsy approaches for precision immuno-oncology
Valsamo K. Anagnostou, Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, Maryland

Targeting myeloid cells that define the tumor immune microenvironment in NSCLC
Thomas U. Marron, Mount Sinai Medical Center Tisch Cancer Institute, New York, New York

Preclinical and translational approaches to capturing mechanisms of immunotherapy response and resistance in NSCLC
Don L. Gibbons, The University of Texas MD Anderson Cancer Center, Houston, Texas

A reservoir of tumor-specific CD8 T cells in lung cancer resides in the draining lymph node*
Nikhil Joshi, Yale University, New Haven, Connecticut


Break
4-4:15 p.m.


Plenary Session 5: Targeting Tumor Suppressors and "Undruggable" Targets
Session Chair: Kris C. Wood, Duke University, Durham, North Carolina
4:15-6 p.m.

Decoding critical targets of LKB1/STK11 in NSCLC
Reuben J. Shaw, Salk Institute, La Jolla, California

A new generation of anti-Myc mini-proteins as potential therapy for NSCLC
Laura Soucek, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain

Druggable vulnerabilities in therapy-resistant lung cancers
Kris C. Wood

Blockade of myeloid suppressor cells overcomes the anti-PD-1/PD-L1 resistance in KRAS-driven and LKB1-deficient NSCLC*
Rui Li, University of California Los Angeles, Los Angeles, California

Proteogenomic characterization reveals therapeutic vulnerabilities in lung adenocarcinoma*
Michael Gillette, Broad Institute of MIT and Harvard, Cambridge, Massachusetts


Top of page


Monday, January 13

Continental Breakfast
7-8 a.m.


Plenary Session 6: Cellular Therapies, Vaccines, and New IO Modalities
Session Chair: Edward B. Garon, University of California Los Angeles, Los Angeles, California
8-9:30 a.m.

A new world for lung cancer vaccines: Beyond picking a single antigen for everyone
Edward B. Garon

Evaluating the role of B cells and tertiary lymphoid structures in lung cancer development and progression
Tullia C. Bruno, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania

Dendritic cell in situ vaccination potentiates anti-PD-1 efficacy and induces immunoediting in a murine model of NSCLC*
Ramin Salehi-Rad, University of California Los Angeles, Los Angeles, California

N-803 plus nivolumab for advanced or metastatic non-small cell lung cancer: Update on phase II experience of combination PD1 blockade with an IL-15 superagonist*
John Wrangle, Medical University of South Carolina, Charleston, South Carolina


Break
9:30-10 a.m.


Plenary Session 7: Small-Cell Lung Cancer
Session Chair: David G. McFadden, UT Southwestern Medical Center, Dallas, Texas
10 a.m.-12:20 p.m.

Pan-cancer convergence to a small-cell neuroendocrine phenotype that shares susceptibilities with hematological malignancies
Thomas G. Graeber, University of California Los Angeles, Los Angeles, California

ASCL1 represses a latent osteogenic program in small-cell lung cancer arising from multiple cells of origin
Trudy G. Oliver, University of Utah Huntsman Cancer Institute, Salt Lake City, Utah

Identifying chemically tractable vulnerabilities in small-cell lung cancer
David G. McFadden

Developing new therapies in small-cell lung cancer using parallel clinical and laboratory-based studies
Anna Farago, Massachusetts General Hospital, Boston, Massachusetts

Targeting DLL3 in small-cell lung cancer with novel modalities
John T. Poirier, Perlmutter Cancer Center at NYU Langone Health, New York, New York

Unraveling the mechanisms of small-cell lung cancer brain metastasis*
Fangfei Qu, Stanford University School of Medicine, Stanford, California


Lunch (on Own)
12:20-2 p.m.


Plenary Session 8: Metastasis and Tumor Progression
Session Chair: David Feldser, University of Pennsylvania, Philadelphia, Pennsylvania
2-3:15 p.m.

Adaptive determinants of metastatic progression in lung adenocarcinoma
Don X. Nguyen, Yale University School of Medicine, New Haven, Connecticut

Stage-specific roles of RB constrain tumor progression, lineage fidelity, and metastasis
David Feldser

Restoring Capicua (CIC) expression to limit lung cancer metastasis
Ross A. Okimoto, University of California San Francisco, San Francisco, California


Panel Discussion: What to Do about Squamous Cell?
Panel Moderator: Trudy G. Oliver, University of Utah Huntsman Cancer Institute, Salt Lake City, Utah
3:20-4:50 p.m.

Eric B. Haura, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Trudy G. Oliver
Paul Paik, Memorial Sloan Kettering Cancer Center, New York, New York
Kwok-Kin Wong, New York University Langone Medical Center, New York, New York

Targeting glucose reliance in lung squamous cell carcinoma*
Jung-whan Kim, University of Texas at Dallas, Richardson, Texas


Poster Session B Highlights
Session Chair: Trever G. Bivona, University of California San Francisco, San Francisco, California
4:55 p.m.

(B01) Active YAP as a functional marker of drug-tolerant persister cells in EGFR-mutant and ALK fusion-positive NSCLC
Franziska Haderk, University of California San Francisco, San Francisco, California

(B02) The GSK3 signaling axis regulates adaptive glutamine metabolism in lung squamous cell carcinoma
Milica Momcilovic, University of California Los Angeles, Los Angeles, California

(B03) JNJ-61186372, an Fc effector enhanced EGFR/cMet bispecific antibody, induces EGFR/cMet downmodulation and efficacy through monocyte and macrophage trogocytosis
Sheri Moores, Janssen Research & Development, Spring House, Pennsylvania
    
(B04) Activity of larotrectinib in tropomyosin receptor kinase fusion lung cancer
Anna Farago, Massachusetts General Hospital Cancer Center, Boston, Massachusetts

(B05) Identifying SCLC vulnerabilities using phenotypic chemical screens
Juan Manuel Povedano Selfa, University of Texas Southwestern Medical Center, Dallas, Texas

(B06) Time-resolved RNA-seq identifies transient gene expression changes following initial chemotherapy challenge in small-cell lung cancer
David Shia, University of California Los Angeles, Los Angeles, California

(B07) Mechanisms of alectinib resistance in a leptomeningeal carcinomatosis of EML4-ALK lung cancer and its circumvention by EGR-TKIs
Seiji Yano, Kanazawa University, Kanazawa, Ishikawa, Japan


Poster Session B
/ Reception
5:15-7:15 p.m.


Top of page


Tuesday, January 14

Continental Breakfast
7-8 a.m.


Plenary Session 9: Genomic Mechanisms of Resistance 
Session Chair: Robert C. Doebele, University of Colorado Denver, Aurora, Colorado  
8-10 a.m.

Title to be announced
Robert C. Doebele

Targeting osimertinib resistance in EGFR-mutant NSCLC: A clinical perspective
Zofia Piotrowska, Massachusetts General Hospital, Boston, Massachusetts

Investigating and overcoming primary resistance of EGFR and HER2 (ERBB2) exon 20 mutant NSCLC
Jacqulyne Robichaux, The University of Texas MD Anderson Cancer Center, Houston, Texas

Genetic contributors to tumor progression and drug resistance in EGFR mutant lung cancer
Katerina A. Politi, Yale Cancer Center, New Haven, Connecticut

Advocate Presentation
Janet Freeman-Daily, Co-Founder, The ROS1ders


Advocate Presentation
Jill Feldman, Co-Founder, EGFR Resisters


Break
10-10:30 a.m.


Plenary Session 10: Nongenetic Mechanisms of Resistance
Session Chair: Christine M. Lovly, Vanderbilt University School of Medicine, Nashville, Tennessee
10:30 a.m.-12:30 p.m.

Nongenetic mechanisms of resistance
Trever G. Bivona, University of California San Francisco, San Francisco, California

Mechanisms of small cell lineage transformation in resistance to targeted therapies
William W. Lockwood, British Columbia Cancer Agency, Vancouver, British Columbia, Canada

The YAP/FOXM1 axis regulates EMT-associated EGFR tyrosine kinase inhibitor resistance and increased expression of spindle assembly checkpoint components
John V. Heymach, The University of Texas MD Anderson Cancer Center, Houston, Texas

Bypass signaling pathways that confer resistance to EGFR and ALK inhibitors
Christine M. Lovly, Vanderbilt University School of Medicine, Nashville, Tennessee

Advocate Presentation
Colin Barton, Executive Board Member, ALK Positive


^not eligible for CME credit

*Short talk from proffered abstract


Top of page